丹麦全国队列:炎症性风湿病患者COVID-19住院发生率与严重程度
丹麦2020年3月1日至8月12日全国队列研究显示,炎症性风湿病患者COVID-19住院调整发生率高于一般人群(HR 1.46,95%CI 1.15–1.86),类风湿关节炎患者风险最高(HR 1.72,95%CI 1.29–2.30)。TNF抑制剂、羟氯喹或糖皮质激素使用与住院风险无关;住院RA患者严重结局HR为1.43(95%CI 0.80–2.53)。
要点
- 炎症性风湿病患者COVID-19住院风险较一般人群升高(HR 1.46)。
- 类风湿关节炎患者住院风险升高更明显(HR 1.72)。
- TNF抑制剂、羟氯喹或糖皮质激素使用未增加住院风险。
核心结论
- 炎症性风湿病患者较一般人群更易因COVID-19住院,住院RA患者可能面临更高严重结局风险。
- 特定DMARD治疗未影响COVID-19住院风险。
研究设计与样本
- 估计RA、脊柱关节炎(含银屑病关节炎)、结缔组织病、血管炎及非IRD个体COVID-19住院调整发生率。
- 分析RA患者使用与未使用TNF抑制剂、羟氯喹或糖皮质激素的住院发生率。
- 评估住院RA与非IRD个体严重COVID-19感染(重症监护、急性呼吸窘迫综合征或死亡)发生率。
主要发现
- 炎症性风湿病患者COVID-19住院部分调整HR为1.46(95%CI 1.15–1.86),对照为一般人群。
- RA患者住院HR为1.72(95%CI 1.29–2.30),血管炎患者HR为1.82(95%CI 0.91–3.64)。
- TNF抑制剂、羟氯喹或糖皮质激素使用与COVID-19住院发生率升高无关。
- 住院RA患者严重结局HR为1.43(95%CI 0.80–2.53),对照为非IRD个体。
临床怎么用
- 应关注炎症性风湿病尤其是RA患者的COVID-19住院风险,住院RA患者需警惕严重结局。
- 不应因担心COVID-19住院风险而停用TNF抑制剂、羟氯喹或糖皮质激素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the incidence of COVID-19 hospitalization in patients with inflammatory rheumatic disease (IRD); in patients with RA treated with specific DMARDs; and the incidence of severe COVID-19 infection among hospitalized patients with RA. METHODS: A nationwide cohort study from Denmark between 1 March and 12 August 2020. The adjusted incidence of COVID-19 hospitalization was estimated for patients with RA; spondyloarthritis including psoriatic arthritis; connective tissue disease; vasculitides; and non-IRD individuals. Further, the incidence of COVID-19 hospitalization was estimated for patients with RA treated and non-treated with TNF-inhibitors, HCQ or glucocorticoids, respectively. Lastly, the incidence of severe COVID-19 infection (intensive care, acute respiratory distress syndrome or death) among hospital-admitted patients was estimated for RA and non-IRD sp - individudals. RESULTS: Patients with IRD (n = 58 052) had an increased partially adjusted incidence of hospitalization with COVID-19 compared with the 4.5 million people in the general population [hazard ratio (HR) 1.46, 95% CI: 1.15, 1.86] with strongest associations for patients with RA (n = 29 440, HR 1.72, 95% CI: 1.29, 2.30) and vasculitides (n = 4072, HR 1.82, 95% CI: 0.91, 3.64). There was no increased incidence of COVID-19 hospitalization associated with TNF-inhibitor, HCQ nor glucocorticoid use. COVID-19 admitted patients with RA had a HR of 1.43 (95% CI: 0.80, 2.53) for a severe outcome. CONCLUSION: Patients with IRD were more likely to be admitted with COVID-19 than the general population, and COVID-19 admitted patients with RA could be at higher risk of a severe outcome. Treatment with specific DMARDs did not affect the risk of hospitalization.
引用
- Cordtz R, Lindhardsen J, Soussi BG, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology (Oxford). 2021. PMID: 33369663. doi:10.1093/rheumatology/keaa897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。